TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Down 55%, Should You Buy the Dip on Pfizer?

The Motley Fool Logo The Motley Fool By Reuben Gregg Brewer
Down 55%, Should You Buy the Dip on Pfizer?

Pfizer's stock has dropped over 55% since its 2021 peak due to post-pandemic market shifts and upcoming patent expirations. Despite challenges, the pharmaceutical giant shows resilience through strategic acquisitions and potential long-term value.

Insights
PFE   neutral

The stock faces challenges like patent expirations in 2027-2028, but demonstrates strategic adaptability through acquisitions and has a history of surviving industry headwinds. The current valuation suggests potential value for long-term investors.